Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Avalo Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 9 filings
- 3 insiders, $2.04M in total
- Insiders trading
- 3
- Net value
- −$2.04M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Avalo Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | 39,900 | Sep 18, 2026 | 12 |
| Doyle Mittie | Chief Medical Officer | 51,776 | Sep 1, 2026 | 16 |
| Riley Jennifer | Chief Strategy Officer | 37,041 | Aug 12, 2026 | 5 |
| Philip Ron M | Director | – | Jul 2, 2026 | 2 |
| Lind Kevin Robert | Director | – | Jul 2, 2026 | 5 |
| Jain Rita | Director | – | Jul 2, 2026 | 5 |
| Varki Paul | Chief Legal Officer | 32,576 | Jun 12, 2026 | 5 |
| Kaplan Gilla | Director | 6,333 | Jun 4, 2026 | 2 |
| Heffernan Michael Thomas | Director | – | Jun 4, 2026 | 1 |
| Kantoff Aaron | Director | 6,333 | Jun 4, 2026 | 2 |
| Truex Samantha | Director | 6,333 | Jun 4, 2026 | 2 |
| Neil Garry Arthur | Chief Executive Officer | 190,314 | May 26, 2026 | 3 |
| Chan Mitchell | Director | 3,166 | May 7, 2026 | 2 |
| Goldman Jonathan | Director | 3,166 | Mar 31, 2026 | 2 |
| Boyd Taylor | Chief Business Officer | – | Mar 2, 2026 | 2 |
| Almenoff June Sherie | Director | 3,167 | Jun 18, 2025 | 0 |
| Persson Magnus | Director | – | Dec 21, 2023 | 0 |
| Armistice Capital, LLC | 10% Owner | 731,458Indirect | Jun 28, 2023 | 0 |
| Armistice Capital Master Fund Ltd. | 10% Owner | 731,458Indirect | Jun 28, 2023 | 0 |
| Boyd Steven | 10% Owner | 731,458Indirect | Jun 28, 2023 | 0 |
| Caissa Capital Management ltd. | 10% Owner | 0 | Jun 27, 2023 | 0 |
| Miller Joseph M | Director | – | Apr 4, 2022 | 0 |
| Smolinski Stephen | Chief Commercial Officer | – | Jan 6, 2022 | 0 |
| Harrell James Archie Jr | Chief Commercial Officer | 36,766 | Dec 14, 2021 | 0 |
| Wilkins H Jeffrey | Chief Medical Officer | 33,373 | Dec 14, 2021 | 0 |
| Greenway Schond L. | CFO | 3,883 | Dec 14, 2021 | 0 |
| Gutry Phil | Director | – | Dec 3, 2021 | 0 |
| Bruhn Suzanne Louise | Director | – | Nov 12, 2021 | 0 |
| Cola Michael F | Chief Executive Officer | – | Oct 4, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 14, 2022 (view filing)5:49 PM ET | Jan 12-14 | 2 days | Armistice Capital, LLC and 2 othersDirector, 10% Owner | PPurchase | +455.0K | $0.9951 | +$452.8K | +1.0%46.1M after | 3 lots |
| Jan 11, 2022 (view filing)6:18 PM ET | Jan 7-11 | 4 days | Armistice Capital, LLC and 2 othersDirector, 10% Owner | PPurchase | +645.0K | $0.9968 | +$642.9K | +1.4%45.6M after | 3 lots |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Wilkins H JeffreyChief Medical Officer | PPurchase | +6.37K | $1.57 | +$10.0K | +23.6%33.4K after | |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Sullivan Christopher RyanChief Accounting Officer | PPurchase | +955 | $1.57 | +$1.50K | +11.9%9.00K after | |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Harrell James Archie JrChief Commercial Officer | PPurchase | +1.09K | $1.57 | +$1.72K | +3.1%36.8K after | |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Neil Garry ArthurChief Scientific Officer | PPurchase | +4.27K | $1.57 | +$6.70K | +5.2%85.6K after | |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Greenway Schond L.CFO | PPurchase | +2.23K | $1.57 | +$3.50K | +135.0%3.88K after | |
| Sep 17, 2021 (view filing)2:25 PM ET | Sep 15-17 | 2 days | Armistice Capital, LLC and 2 othersDirector, 10% Owner | PPurchase | +5.70M | $2.20 | +$12.6M | +14.5%45.0M after | 3 lots |
| Aug 18, 2021 (view filing)5:54 PM ET | Aug 16-18 | 2 days | Armistice Capital, LLC and 2 othersDirector, 10% Owner | PPurchase | +50.0K | $2.76 | +$138.2K | +0.1%39.3M after | 2 lots |
| Aug 6, 2021 (view filing)3:15 PM ET | Aug 4-6 | 2 days | Armistice Capital, LLC and 2 othersDirector, 10% Owner | PPurchase | +150.0K | $2.72 | +$408.5K | +0.4%39.3M after | 3 lots |